Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company’s web site at www.cyclacel.com.
- 18 years ago
QualityStocks
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded…
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…